Evidence map›Paper›PMID 40070033›Full record

ArticleJournal of the American Chemical Society2025

Identification of a Selective Anticancer Agent from a Collection of Complex-And-Diverse Compounds Synthesized from Stevioside.

Rachel E Schaaf, Jonathan C K Quirke, Maryam Ghavami, Emily J Tonogai, Hyang Yeon Lee, Samantha L Barlock, Thomas R Trzupek, Kyle R Abo, Matthew G Rees, Melissa M Ronan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthesis through C(spAccounts of chemical research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rachel E SchaafDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Jonathan C K QuirkeDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Maryam GhavamiDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Emily J TonogaiDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Hyang Yeon LeeDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Samantha L BarlockDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Thomas R TrzupekDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Kyle R AboDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Matthew G ReesBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, Massachusetts 02142, United States.
Melissa M RonanBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, Massachusetts 02142, United States.
Jennifer A RothBroad Institute of MIT and Harvard, 415 Main Street, Cambridge, Massachusetts 02142, United States.
Paul J HergenrotherDepartment of Chemistry, Cancer Center at Illinois, Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0001-9018-3581

Funding

Developing a Suite of Targeted Anticancer DrugsR35CA283859 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Paul Hergenrother · 2023 to 2026
$2.8M
NCI NIH HHS R35 CA283859
6 · The paper itself

Abstract

Compounds constructed by distorting the ring systems of natural products serve as a ready source of complex and diverse molecules, useful for a variety of applications. Herein is presented the use of the diterpenoids steviol and isosteviol as starting points for the construction of >50 new compounds through this complexity-to-diversity approach, featuring novel ring system distortions and a noteworthy thallium(III) nitrate (TTN)-mediated ring fusion. Evaluation of this collection identified

Indexed as

Antineoplastic AgentsDiterpenes, KauraneGlucosidesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFerroptosisHumansMolecular StructurePhospholipid Hydroperoxide Glutathione PeroxidaseStructure-Activity RelationshipAntineoplastic AgentsDiterpenes, KauraneGlucosidesPhospholipid Hydroperoxide Glutathione Peroxidase

Identifiers

PMID40070033
PMCPMC12232552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.